CTI BioPharma Corp

NASDAQ:CTIC  
4.69
-0.18 (-3.70%)
4:50:28 PM EDT: $4.69 0.00 (0.00%)
Earnings Announcements

CTI Biopharma Reports Fourth Quarter And Full Year 2021 Financial Results

Published: 03/31/2022 20:31 GMT
CTI BioPharma Corp (CTIC) - Cti Biopharma Reports Fourth Quarter and Full Year 2021 Financial Results.
Q4 Loss per Share $0.38.
Expect Current Cash and Cash Equivalents Will Enable to Fund Operations Into Q4 of 2022.
Q4 Earnings per Share View $-0.28 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $8.43 Million
Adjusted EPS is expected to be -$0.19

Next Quarter Revenue Guidance is expected to be $15.71 Million
Next Quarter EPS Guidance is expected to be -$0.15

More details on our Analysts Page.